Advisor Group’s Zynerba Pharmaceuticals, Inc ZYNE Stock Holding History

Advisor Group’s Portfolio ZYNE Stock Details ZYNE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q4	$28K	Sell	4,773 -50	-1%	-$342	﹤0.01%	3783
2019 Q3	$37K	Buy	4,823 +2,882	+148%	+$32.5K	﹤0.01%	3595
2019 Q2	$27K	Buy	1,941 +910	+88%	+$10.5K	﹤0.01%	3786
2019 Q1	$6K	Hold	1,031	–	–	﹤0.01%	4621
2018 Q4	$3K	Hold	1,031	–	–	﹤0.01%	4752
2018 Q3	$8K	Hold	1,031	–	–	﹤0.01%	4406
2018 Q2	$10K	Hold	1,031	–	–	﹤0.01%	4089
2018 Q1	$9K	Hold	1,031	–	–	﹤0.01%	4161
2017 Q4	$13K	Buy	1,031 +300	+41%	+$3.44K	﹤0.01%	3953
2017 Q3	$6K	Sell	731 -80	-10%	-$846	﹤0.01%	4225
2017 Q2	$14K	Sell	811 -420	-34%	-$8.35K	﹤0.01%	3753
2017 Q1	$25K	Buy	1,231 +500	+68%	+$9.94K	﹤0.01%	3237
2016 Q4	$11K	Buy	+731	New	+$9.85K	﹤0.01%	3586

Other funds holding ZYNE

EMG

ETF Managers Group Summit, New Jersey $3.1B AUM 17.12% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

PCM

Portolan Capital Management Boston, Massachusetts $1.88B AUM 115.74% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ZCA

Zeke Capital Advisors Berwyn, Pennsylvania $1.53B AUM 17.37% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return

Advisor Group's ZYNE Position: Q4 2019 in Review

Advisor Group reduced its Zynerba Pharmaceuticals, Inc (ZYNE) stake by 1% in Q4 2019, selling an estimated $342 and leaving 4,773 shares worth $28K. The position accounts for ﹤0.01% of the portfolio, ranked #3783.

Advisor Group first reported a position in ZYNE in Q4 2016 and has held it in 13 quarters since. The position peaked at $37K in Q3 2019. 79 funds tracked by Wall St. Rank hold ZYNE as of Q4 2019.

Advisor Group held 4,773 shares of Zynerba Pharmaceuticals, Inc worth $28K as of Q4 2019.
Advisor Group sold 50 Zynerba Pharmaceuticals, Inc shares in Q4 2019, an estimated $342.
Zynerba Pharmaceuticals, Inc made up ﹤0.01% of Advisor Group's portfolio in Q4 2019, its #3783 holding.
Advisor Group first reported a position in Zynerba Pharmaceuticals, Inc in Q4 2016 and has held it in 13 quarters since.
Advisor Group's Zynerba Pharmaceuticals, Inc position peaked at $37K in Q3 2019.
79 funds tracked by Wall St. Rank held Zynerba Pharmaceuticals, Inc as of Q4 2019.

Based on Advisor Group's 13F filing for Q4 2019, filed 12 Feb 2020.